Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01746849 · ClinicalTrials.gov registry record · Phase 2

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

A Phase 2 study of Multiple Myeloma and Leukemia, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 2
Development phase
82
Enrollment target
1
Study location

NCT01746849 is a Phase 2 study of Multiple Myeloma and Leukemia that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 82 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01746849, a Phase 2 study of Multiple Myeloma and Leukemia, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
82 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to help determine if palifermin and leuprolide acetate can help the immune system recover faster following a stem cell transplant. Blood stem cells are very young blood cells that grow in the body to become red or white blood cells or platelets. The transplant uses stem cells in the blood from another person. The donor can be a family member or a volunteer donor. This is called an allogeneic stem cell transplant. The investigators want to see if palifermin and leuprolide acetate can help the immune system recover faster after an allogenic transplant because experiments have shown they may be able to do this.

Conditions Studied

Multiple Myeloma Leukemia Myelodysplastic Syndrome Non-Hodgkin's Lymphoma

Interventions

  • DRUG Thiotepa
  • BIOLOGICAL Palifermin
  • BIOLOGICAL Lupron
  • PROCEDURE peripheral blood stem cell transplantation
  • RADIATION Total-Body Irradiation (TBI)

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 82 participants
Start Date 2012-12
Est. Completion 2026-12
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01746849

The ClinicalTrials.gov registry entry for NCT01746849 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (85% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Thiotepa is the first listed.

NCT01746849 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT01746849 about?

NCT01746849 is a clinical study titled "Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation". The purpose of this study is to help determine if palifermin and leuprolide acetate can help the immune system recover faster following a stem cell transplant. Blood stem cells are very young blood cells that grow in the body to become red or white blood cells or platelets. The transplant uses stem ...

What is the current status of trial NCT01746849?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2012-12. Estimated completion is 2026-12.

What conditions does trial NCT01746849 study?

This clinical trial studies the following conditions: Multiple Myeloma, Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma.

What interventions are being tested in trial NCT01746849?

The interventions under investigation include: Thiotepa (DRUG), Palifermin (BIOLOGICAL), Lupron (BIOLOGICAL), peripheral blood stem cell transplantation (PROCEDURE), Total-Body Irradiation (TBI) (RADIATION).

Who is sponsoring clinical trial NCT01746849?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01746849 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Leukemia

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.